Edwards Lifesciences (NYSE:EW) Price Target Raised to $100.00

Edwards Lifesciences (NYSE:EW) had its price target hoisted by Wells Fargo & Company from $96.00 to $100.00 in a research report report published on Wednesday,Benzinga reports. They currently have an overweight rating on the medical research company’s stock.

A number of other equities research analysts also recently issued reports on EW. UBS Group reissued a “neutral” rating and issued a $94.00 price target on shares of Edwards Lifesciences in a research note on Wednesday, February 4th. JPMorgan Chase & Co. upgraded shares of Edwards Lifesciences from a “neutral” rating to an “overweight” rating and lifted their target price for the company from $90.00 to $100.00 in a report on Thursday, December 18th. Evercore restated an “outperform” rating and set a $94.00 price target on shares of Edwards Lifesciences in a research note on Monday, January 5th. Sanford C. Bernstein restated a “market perform” rating and set a $90.00 price target on shares of Edwards Lifesciences in a research report on Monday, November 3rd. Finally, Barclays reaffirmed an “overweight” rating and issued a $104.00 price objective (up from $103.00) on shares of Edwards Lifesciences in a research note on Monday, January 12th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $96.14.

Edwards Lifesciences Stock Down 0.8%

Shares of NYSE EW opened at $75.80 on Wednesday. The company has a market capitalization of $43.99 billion, a P/E ratio of 41.42, a P/E/G ratio of 2.00 and a beta of 0.94. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.00 and a quick ratio of 3.29. The company has a 50 day simple moving average of $83.34 and a 200-day simple moving average of $81.08. Edwards Lifesciences has a 1 year low of $65.94 and a 1 year high of $87.89.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Tuesday, February 10th. The medical research company reported $0.58 EPS for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). The business had revenue of $1.57 billion during the quarter, compared to analyst estimates of $1.54 billion. Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The company’s revenue was up 13.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.59 earnings per share. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. On average, equities research analysts predict that Edwards Lifesciences will post 2.45 earnings per share for the current year.

Insiders Place Their Bets

In related news, VP Donald E. Bobo, Jr. sold 11,340 shares of the company’s stock in a transaction that occurred on Tuesday, January 6th. The shares were sold at an average price of $85.66, for a total transaction of $971,384.40. Following the sale, the vice president directly owned 31,870 shares in the company, valued at approximately $2,729,984.20. This represents a 26.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Scott B. Ullem sold 7,700 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, December 9th. The stock was sold at an average price of $84.47, for a total transaction of $650,419.00. Following the completion of the transaction, the chief financial officer owned 39,898 shares of the company’s stock, valued at $3,370,184.06. This represents a 16.18% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 43,804 shares of company stock worth $3,699,082 in the last quarter. 1.29% of the stock is owned by company insiders.

Institutional Investors Weigh In On Edwards Lifesciences

Institutional investors have recently added to or reduced their stakes in the business. Norges Bank acquired a new stake in Edwards Lifesciences during the fourth quarter worth approximately $803,686,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its holdings in shares of Edwards Lifesciences by 111.2% in the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 9,129,357 shares of the medical research company’s stock valued at $714,006,000 after buying an additional 4,805,819 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Edwards Lifesciences by 278.3% in the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company’s stock valued at $434,318,000 after buying an additional 4,108,270 shares during the last quarter. Marshall Wace LLP raised its stake in Edwards Lifesciences by 127.5% during the 2nd quarter. Marshall Wace LLP now owns 6,895,579 shares of the medical research company’s stock worth $539,303,000 after acquiring an additional 3,864,908 shares in the last quarter. Finally, Viking Global Investors LP acquired a new stake in Edwards Lifesciences during the 3rd quarter worth $238,688,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.